Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
Lipocine announces results from phase 2 trial for obesity drug
April 12, 2024Research and Development Lipocine, Obesity, clinical trial, weight loss
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Baxter expands US portfolio with new injectables
April 12, 2024Medical Communications Pharmacy, baxter, injectables, product launch
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …
Vertex to acquire Alpine Immune Sciences for $4.9bn
April 11, 2024Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
April 10, 2024Research and Development FDA, Oncology, Oryzon, lung cancer
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
An overview of women’s health in 2024
April 9, 2024Reproductive health, abortion, fertility, reproductive health, women's health
Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
PureTech Health launches Seaport Therapeutics
April 9, 2024Business Services Financing, Neurology, PureTech Health, launch
PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
April 8, 2024Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …
Johnson & Johnson to acquire Shockwave Medical
April 8, 2024Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition
Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
April 5, 2024Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
FDA accepts UCB’s sBLA for Bimzelx
April 5, 2024Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …
FDA approves Basilea’s antibiotic Zevtera for three indications
April 4, 2024Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic
Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), …
Ironic Biotech announces $1m funding to develop iron deficiency and anaemia treatment
April 4, 2024Sales and Marketing Haematology, Ironic Biotech, anaemia, funding, iron deficiency
Swedish biotech startup Ironic Biotech has announced that it has successfully closed a pre-seed funding round of $1m, led by …
FDA approves Eko Health’s AI for heart failure detection
April 3, 2024Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction
Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …
EnteroBiotix begins phase 2 trial of IBS treatment
April 3, 2024Research and Development EnteroBiotix, Gastrointestinal tract, IBS, irritable bowel syndrome
EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
April 2, 2024Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
